Tavanta Therapeutics to Showcase Specialty Pipeline During the 2023 American Society of Clinical Oncology (ASCO) and American Society of Colon and Rectal Surgeons (ASCRS) Annual Congresses
"At ASCRS, we are excited to present the first data from our Phase 2 study of TAVT-119 in people with anal fissure.
- "At ASCRS, we are excited to present the first data from our Phase 2 study of TAVT-119 in people with anal fissure.
- Currently, non-surgical options to treat anal fissures include topical nitrates (which are limited by headache/tolerability) and topical calcium channel blockers (which are only available via compounding pharmacies as none are FDA-approved for anal fissure).
- Based on the data that will be presented, we believe that TAVT-119 has the potential to offer patients a therapeutic option that is safe, efficacious and accessible."
- "We are pleased to highlight these promising new data, which reflect the significant progress of our clinical development programs," said Lynne Powell, Chief Executive Officer of Tavanta Therapeutics.